TriSalus Life Sciences Announces Board and Officer Changes
Ticker: TLSIW · Form: 8-K · Filed: Oct 1, 2025 · CIK: 1826667
| Field | Detail |
|---|---|
| Company | Trisalus Life Sciences, Inc. (TLSIW) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, leadership-change, officer-appointment, director-election
TL;DR
TriSalus Life Sciences shakes up its board and exec team effective Sept 30.
AI Summary
TriSalus Life Sciences, Inc. filed an 8-K on October 1, 2025, reporting changes effective September 30, 2025. The filing details the departure of directors, election of new directors, appointment of officers, and information regarding compensatory arrangements for certain officers. The company, formerly known as MedTech Acquisition Corp, is incorporated in Delaware and operates in the surgical and medical instruments sector.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership and governance can introduce uncertainty and signal potential strategic shifts, which carry inherent risks.
Key Numbers
- 001-39813 — SEC File Number (Identifies the company's filings with the SEC.)
- 853009869 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- TriSalus Life Sciences, Inc. (company) — Registrant
- MedTech Acquisition Corp (company) — Former company name
- September 30, 2025 (date) — Effective date of changes
- October 1, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific reasons were given for the departure of directors?
The filing indicates the departure of directors but does not specify the reasons in the provided text.
Who are the newly elected directors?
The filing mentions the election of directors but does not list their names in the provided text.
What are the details of the compensatory arrangements for the officers?
The filing notes that compensatory arrangements of certain officers are being reported, but the specific details are not included in the provided text.
When did TriSalus Life Sciences, Inc. change its name from MedTech Acquisition Corp?
The date of the name change from MedTech Acquisition Corp to TriSalus Life Sciences, Inc. was September 30, 2020.
What is the principal executive office address of TriSalus Life Sciences, Inc.?
The principal executive office is located at 6272 W 91st Ave, Westminster, Colorado 80031.
Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-10-01 16:28:58
Key Financial Figures
- $0.0001 — ange on which registered Common stock, $0.0001 par value TLSI Nasdaq Global Market
- $11.50 — 's common stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Market
Filing Documents
- tlsi-20250930.htm (8-K) — 25KB
- 0001628280-25-043440.txt ( ) — 179KB
- tlsi-20250930.xsd (EX-101.SCH) — 2KB
- tlsi-20250930_def.xml (EX-101.DEF) — 16KB
- tlsi-20250930_lab.xml (EX-101.LAB) — 27KB
- tlsi-20250930_pre.xml (EX-101.PRE) — 16KB
- tlsi-20250930_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 1, 2025 TriSalus Life Sciences, Inc. By: /s/ David Patience Name: David Patience Title: Chief Financial Officer